Actively Recruiting
Balloon Angioplasty for Minor Unstable Stroke With IntraCranial Atherosclerosis Stenosis (BAMUS-ICAS)
Led by General Hospital of Shenyang Military Region · Updated on 2026-04-27
100
Participants Needed
1
Research Sites
149 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Intracranial atherosclerotic stenosis (ICAS) is a common cause of stroke, especially in East and South Asia, and is significantly associated with stroke recurrence and early neurological deterioration (END) despite aggressive medical management. Minor stroke (National Institutes of Health Stroke, NIHSS score ≤ 5) patients with ICAS often has higher risk of END. The early realization of blood flow patency is closely related to the improvement of patient outcomes. Submaximal balloon angioplasty (SBA) as a safer and simpler intervention which can improve cerebral blood flow. Thus, SBA may be an effective strategy for preventing END in acute ischemic stroke patients with ICAS.
CONDITIONS
Official Title
Balloon Angioplasty for Minor Unstable Stroke With IntraCranial Atherosclerosis Stenosis (BAMUS-ICAS)
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Over 18 years of age
- Minor ischemic stroke within 1 week of onset with NIHSS score of 5 or less
- Received best drug treatment (dual antiplatelet plus anticoagulation) but symptoms still fluctuate or progress (NIHSS increase by at least 1 point)
- Symptoms fluctuate up to the time of receiving balloon dilation within 24 hours
- Severe narrowing (70-99%) of responsible intracranial vessels or perforator artery disease confirmed by imaging (MRA, CTA, or DSA)
- First stroke or past stroke without disabling sequelae affecting NIHSS score; mRS score less than 2 if past onset
- Patient or family provides signed informed consent
You will not qualify if you...
- Large intracranial vessel occlusion
- Intracranial hemorrhagic diseases in past 3 months (e.g., cerebral hemorrhage, subarachnoid hemorrhage)
- Non-atherosclerotic stenosis causes (arterial dissection, moya-moya disease, arterioinflammatory disease)
- Clotting disorders, systemic bleeding tendencies, or platelets below 100,000
- Serious infections or severe liver, kidney, or other diseases
- Severe uncontrolled hypertension (systolic >200 mmHg or diastolic >110 mmHg)
- Women who are pregnant, planning pregnancy, or breastfeeding
- Other serious diseases with life expectancy less than 6 months or conditions deemed unsuitable for participation
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
General Hospital of Northern Theater Command
Shenyang, China, 110840
Actively Recruiting
Research Team
H
Hui-Sheng Chen
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
SINGLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here